Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › North Carolina › Durham
Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa Durham, NC keessatti
Qorannoo 27 Luukemiya Limfoositiikii Keessummaa f Durham fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Durham VA Medical Center, Durham
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Namoota walitti qabaa jiraSadarkaa 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
- University of North Carolina-Hillsborough Campus, Hillsborough · Miili 13 fagaatti
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Namoota walitti qabaa jiraSadarkaa 3
- University of North Carolina At Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
- University of North Carolina At Chapel Hill, Chapel Hill · Miili 10 fagaatti
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Namoota walitti qabaa jiraSadarkaa 3
- Duke University, Durham
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Namoota walitti qabaa jiraSadarkaa 2
- Duke University, Durham
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Namoota walitti qabaa jiraSadarkaa 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · Miili 10 fagaatti
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Namoota walitti qabaa jiraSadarkaa 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · Miili 10 fagaatti
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Durham
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Duke University Medical Center, Durham
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Namoota walitti qabaa jira
- North Carolina Basnight Cancer Hospital, Chapel Hill · Miili 10 fagaatti
Registry of Older Patients With Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Miili 10 fagaatti
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 4
- Duke University Medical Center, Durham
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Namoota walitti qabaa jiraSadarkaa 4
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
Namoota walitti qabaa jiraSadarkaa 1
- Duke University, Durham
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina /ID# 233313, Chapel Hill · Miili 10 fagaatti
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Namoota walitti qabaa jiraSadarkaa 2
- The University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Namoota walitti qabaa jiraSadarkaa 2
- Durham VA Medical Center, Durham, NC, Durham
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Duke University, Durham
Qorannoo Luukemiya Limfoositiikii Keessummaa magaalota biroo keessatti
- Boston, MAQorannoo 31
- Columbus, OHQorannoo 28
- Washington, DCQorannoo 22
- Seattle, WAQorannoo 20
- Rochester, MNQorannoo 19
- New York City, NYQorannoo 18
- Houston, TXQorannoo 17
- Baldwin Park, CAQorannoo 16
- Milwaukee, WIQorannoo 15
- Cincinnati, OHQorannoo 14
- Chicago, ILQorannoo 14
- Nashville, TNQorannoo 13
Qorannoo biroo Durham keessatti
- Saree OljooQorannoo 63
- Saree (Gosoota Hunda)Qorannoo 58
- Kansara Qara'a Non-Small CellQorannoo 39
- Myeloma Baay’eeQorannoo 37
- Kansara MetastatikiiQorannoo 33
- Leukemia Myeloidii HamaaQorannoo 33
- Dhibee QaraQorannoo 32
- Kansarii ProstateQorannoo 32
- Kansarii ColorectalQorannoo 28
- Kansarii OvariiQorannoo 27
- Cufama OnneeQorannoo 26
- Kansarii PancreasQorannoo 24
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.